Meropenem-Vaborbactam

ApprovedSmall molecule

MMelinta Therapeutics, Inc.

Meropenem-Vaborbactam is one of 77 small molecule programs targeting Bacterial Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial PneumoniaActive, not recruiting

Gram-Negative Bacterial InfectionsActive, not recruiting

Urinary Tract InfectionActive, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

Gram-Negative Bacterial InfectionsApproved

Active, not recruiting

Urinary Tract InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

163 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Maxipime

Pfizer

Phase 3

3 2

Medrol

Pfizer

Phase 3

1 3

Merrem

BB. Braun Medical Inc.

Phase 3

7 4

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

2 5

Decadron

AAspen Global Incorporated

Phase 3

1 6

Comparator: Pbo

Merck & Co.

Phase 3

2 7

Piperacillin/tazobactam

Pfizer

Phase 3

1 8

Prulifloxacin

Merck & Co.

Phase 3

1 9

Meropenem-Vaborbactam

MMelinta Therapeutics, Inc.

Approved

1 10

Amoxicillin/clavulanate Potassium

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Urinary Tract Infection

NCT06672978

Q4 2028

Post-ApprovalRecruiting

Gram-Negative Bacterial Infections

NCT07004049

Clinical

Trials by Indication[1]

Meropenem2 trials

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT02166476·550 enrolled

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT03564158·53 enrolled

Gram-Negative Bacterial Infections1 trial

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting·NNational University of Singapore·Phase 4·NCT07004049·600 enrolled

Bacterial Pneumonia1 trial

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Withdrawn·MMelinta Therapeutics, Inc.·Phase 3·NCT03006679

Urinary Tract Infection1 trial

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Recruiting·MMelinta Therapeutics, Inc.·Phase 2·NCT06672978·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Meropenem-Vaborbactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meropenem-Vaborbactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meropenem-Vaborbactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Melinta Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMelinta Therapeutics, Inc.

Meropenem-Vaborbactam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Meropenem2 trials

Gram-Negative Bacterial Infections1 trial

Bacterial Pneumonia1 trial

Urinary Tract Infection1 trial

References

Drug Info

Quick Facts

Related News